Australia's CSL hit with shareholder class action suit over earnings guidance
Australia's CSL hit with shareholder class action suit over earnings guidance
CSL
Services: Global biopharmaceutical group; CSL Behring develops plasma-derived and recombinant therapeutic products for bleeding disorders, immune deficiencies, CIDP, hereditary angioedema, and Alpha-1 Antitrypsin Deficiency; Seqirus produces influenza vaccines; CSL Vifor addresses iron deficiency and nephrology
Company Info
Sector:Plasma-derived Therapies / Vaccines
Headquarters:Parkville, Melbourne, Australia
Founded:1916
Website:www.csl.com/
Upcoming Milestones & Key Dates
Q3/Q4 2026
Earnings
Q2 2026 earnings call
Recent News
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
CSL has agreed to pay up to $1.6 billion to co-develop an Alentis Therapeutics drug for autoimmune disease, pairing the Australian company's commercial reach with a claudin-targeting candidate.
Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast
Latest Reuters Biopharma coverage of Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast
CSL projects a return to growth for plasma unit Behring
CSL projects a return to growth for plasma unit Behring